Nocturia - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Nocturia – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Nocturia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Nocturia: Overview
Nocturia is a condition that causes you to wake up during the night to urinate. This can be thought of as nocturnal urinary frequency — having to urinate more often at night. This condition becomes more common as people age and occurs in both men and women. Nocturia can be caused by: Polyuria: when a body makes too much urine in a 24-hour period, Nocturnal polyuria: when a body makes too much urine during the night, Bladder storage problems: when a bladder doesn't store or release urine well. Mixed nocturia: when more than one of these problems are happening. Nocturia can have significant health consequences. It may be connected to serious underlying problems, and nighttime bathroom trips can both disrupt sleep and create additional health concerns. Anticholinergic medications (these can reduce symptoms of an overactive bladder), Bumetanide (Bumex®), Furosemide (Lasix®) (diuretics that assist in regulating urine production), Desmopressin (DDAVP®) (helps the kidneys produce less urine) might be helpful in treating the condition.
'Nocturia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nocturia pipeline landscape is provided which includes the disease overview and Nocturia treatment guidelines. The assessment part of the report embraces, in depth Nocturia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nocturia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Nocturia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nocturia Emerging Drugs
Further product details are provided in the report
Nocturia: Therapeutic Assessment
This segment of the report provides insights about the different Nocturia drugs segregated based on following parameters that define the scope of the report, such as:
Nocturia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nocturia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nocturia drugs.
Nocturia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Nocturia – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Nocturia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Nocturia: Overview
Nocturia is a condition that causes you to wake up during the night to urinate. This can be thought of as nocturnal urinary frequency — having to urinate more often at night. This condition becomes more common as people age and occurs in both men and women. Nocturia can be caused by: Polyuria: when a body makes too much urine in a 24-hour period, Nocturnal polyuria: when a body makes too much urine during the night, Bladder storage problems: when a bladder doesn't store or release urine well. Mixed nocturia: when more than one of these problems are happening. Nocturia can have significant health consequences. It may be connected to serious underlying problems, and nighttime bathroom trips can both disrupt sleep and create additional health concerns. Anticholinergic medications (these can reduce symptoms of an overactive bladder), Bumetanide (Bumex®), Furosemide (Lasix®) (diuretics that assist in regulating urine production), Desmopressin (DDAVP®) (helps the kidneys produce less urine) might be helpful in treating the condition.
'Nocturia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nocturia pipeline landscape is provided which includes the disease overview and Nocturia treatment guidelines. The assessment part of the report embraces, in depth Nocturia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nocturia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Nocturia R&D. The therapies under development are focused on novel approaches to treat/improve Nocturia.
This segment of the Nocturia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nocturia Emerging Drugs
- Fedovapagon: Vantia Therapeutics
- FE 201836: Ferring Pharmaceuticals
Further product details are provided in the report
Nocturia: Therapeutic Assessment
This segment of the report provides insights about the different Nocturia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Nocturia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Nocturia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nocturia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nocturia drugs.
Nocturia Report Insights
- Nocturia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Nocturia drugs?
- How many Nocturia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nocturia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nocturia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nocturia and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Nocturia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nocturia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Nocturia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nocturia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase II/III)
Comparative Analysis
Fedovapagon: Vantia Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
FE 201836: Ferring Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
USRP 003: Kao Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Nocturia Key Companies
Nocturia Key Products
Nocturia- Unmet Needs
Nocturia- Market Drivers and Barriers
Nocturia- Future Perspectives and Conclusion
Nocturia Analyst Views
Nocturia Key Companies
Appendix
Executive Summary
Nocturia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nocturia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Nocturia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nocturia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase II/III)
Comparative Analysis
Fedovapagon: Vantia Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
FE 201836: Ferring Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
USRP 003: Kao Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Nocturia Key Companies
Nocturia Key Products
Nocturia- Unmet Needs
Nocturia- Market Drivers and Barriers
Nocturia- Future Perspectives and Conclusion
Nocturia Analyst Views
Nocturia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Nocturia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Nocturia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Nocturia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Nocturia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
